# Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

> **NCT04726553** · EARLY_PHASE1 · UNKNOWN · sponsor: **Oklahoma Medical Research Foundation** · enrollment: 20 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** Anifrolumab
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT04726553
- **Lead sponsor:** Oklahoma Medical Research Foundation
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-20
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-03-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04726553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04726553, "Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04726553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*